Barr To Pay $142M To Settle Patent Dispute With Organon

Law360, New York (September 8, 2005, 12:00 AM EDT) -- U.S. drug maker Barr Pharmaceuticals will pay Dutch rival Organon International $142 million to settle a patent lawsuit over a generic version of the oral contraceptive Mircette.

Organon, a subsidiary of Dutch industrial conglomerate Akzo Nobel, and Duramed Pharmaceuticals Inc., a subsidiary of Barr Pharmaceuticals, have signed a non-binding letter of intent to settle the pending patent lawsuit concerning a generic version of Mircette, the two companies said in a statement.

Under the terms of the agreement, Barr Pharmaceuticals will acquire all rights relating to Mircette,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.